卵巢癌组织中EphA2受体蛋白的表达

Expression of EphA2 receptor in ovarian cancer tissue

目的:探讨卵巢癌组织中EphA2受体蛋白的表达及其评价预后的价值。方法:应用免疫组织化学法对 135例卵巢癌组织进行EphA2检测,对其中15例不同级别EphA2蛋白表达的冰冻组织标本,应用激光捕获显微切 割技术(LCM)捕获卵巢癌细胞,应用Western印迹分析方法检测其蛋白表达水平。结果:在135例卵巢癌组织中, EphA2蛋白阳性表达率为91.1%,分别为(-)12例(8.9%),(+)75例(55.6%),( )30例(22.2%),( )18例 (13.3%)。EphA2蛋白表达与卵巢癌患者的年龄、FIGO分期、组织学类型、组织分化程度以及残余肿瘤大小均无 关(P>0.05)。平均生存时间在EphA2蛋白染色强度-～+组与 ～ 组间差异有统计学意义(P<0.05),且 Western印迹结果与免疫组织化学结果一致。结论:EphA2蛋白高表达与卵巢癌患者生存差有关,具有潜在的预测 预后价值。

Aim:To investigate the expression of EphA2 and its predictive value on prognosis in epithelial ovarian carcinomas tissue. Methods: A total of 135 Norwegian patients with ovarian carcinoma were included in this study. Immunohistochemical method was used to detect the expression of EphA2.Frozen tissues from 15 cases with positive EphA2 protein expression were undergone laser capture microdissection(LCM).Cancer cells in each frozen section were captured with the LCM method and processed for Western blot analysising. Results: Among the 135 cases, 12(8.9%), 75(55.6%), 30 (22.2%), 18(13.3%) were immunohistochemically negative, weak, moderate, and strong for EphA2 protein expression, respectively. Consistent results were obtained for the 15 tumors simultaneously detected by both immunohistochemistry and Western blot. The expression level of EphA2 did not correlate with age, FIGO stage, histological type, histological grade, and residual tumour size(P>0.05). Patients with lower EphA2 expression showed longer survival time compared with those with a higher score(P<0.05). Conclusion: Tumors with higher level of EphA2 protein expression is significantly associated with poorer clinical course.